📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Prevencio

1.1 - Company Overview

Prevencio Logo

Prevencio

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of multi-proteomic cardiovascular blood tests: HART CVE uses a machine learning algorithm to predict 1-year risk of heart attack, stroke, or cardiac death; HART CADhs detects obstructive coronary artery disease; HART PAD diagnoses obstructive peripheral artery disease; HART AS diagnoses and monitors aortic valve stenosis (98% exclusion accuracy); HART Amputation Risk assesses amputation risk (87% accuracy).

Products and services

  • HART AS: A biomarker-based blood test diagnosing and monitoring the progression of aortic valve stenosis, predicting with 98% accuracy to exclude severe aortic stenosis
  • HART CADhs™: A multi-proteomic diagnostic blood test for obstructive coronary artery disease, evaluating three blood proteins and three clinical variables to deliver a personalized risk score
  • HART CVE™: A machine-learning–driven prognostic blood test calculating 1-year risk of heart attack, stroke, or cardiac death by analyzing four blood proteins

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Prevencio

X-Ceptor Therapeutics Logo

X-Ceptor Therapeutics

HQ: United States Website
  • Description: Provider of novel small molecule therapeutics that modulate nuclear receptors, along with a drug discovery platform for the nuclear receptor gene family, developing candidates to treat cardiovascular and metabolic disorders.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full X-Ceptor Therapeutics company profile →
Spectranetics Logo

Spectranetics

HQ: United States Website
  • Description: Provider of excimer laser technology for minimally invasive cardiovascular procedures, marketing the only Excimer Laser System and offering a digital Instructions for Use Library with product manuals and usage guidance.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Spectranetics company profile →
ViOptix Logo

ViOptix

HQ: United States Website
  • Description: Provider of innovative proprietary tissue oximetry solutions measuring oxygen saturation levels in tissues, including near infrared generators and single-use disposable sensors, plus systems: T.Ox for real-time, non-invasive monitoring following surgery; T.Ox Remote for Wi-Fi access to oxygenation data; and Intra.Ox for handheld perfusion assessments.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full ViOptix company profile →
Vdyne Logo

Vdyne

HQ: United States Website
  • Description: Provider of proprietary transcatheter valve technology to treat tricuspid regurgitation via a unique side-delivery method, enabling treatment for a broader patient population; developing tricuspid replacement valve and repair technology.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Vdyne company profile →
Omeicos Logo

Omeicos

HQ: Germany Website
  • Description: Provider of first-in-class small-molecule therapeutics based on omega-3 fatty acid metabolites for the treatment and prevention of atrial fibrillation and broader indications. Offers OMT-28, a synthetic analog of 17,18-EEQ for cardiovascular inflammation and mitochondrial dysfunction; conducts the PMD-OPTION study in Primary Mitochondrial Disease; and develops a pipeline of proprietary omega-3 analogs for cardiovascular, inflammatory, and mitochondrial diseases.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Omeicos company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Prevencio

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Prevencio

2.2 - Growth funds investing in similar companies to Prevencio

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Prevencio

4.2 - Public trading comparable groups for Prevencio

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Prevencio

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Prevencio

What does Prevencio do?

Prevencio is a provider of multi-proteomic cardiovascular blood tests: HART CVE uses a machine learning algorithm to predict 1-year risk of heart attack, stroke, or cardiac death; HART CADhs detects obstructive coronary artery disease; HART PAD diagnoses obstructive peripheral artery disease; HART AS diagnoses and monitors aortic valve stenosis (98% exclusion accuracy); HART Amputation Risk assesses amputation risk (87% accuracy).

Who are Prevencio's competitors?

Prevencio's competitors and similar companies include X-Ceptor Therapeutics, Spectranetics, ViOptix, Vdyne, and Omeicos.

Where is Prevencio headquartered?

Prevencio is headquartered in United States.

How many employees does Prevencio have?

Prevencio has 1,000 employees 🔒.

When was Prevencio founded?

Prevencio was founded in 2010 🔒.

What sector and industry vertical is Prevencio in?

Prevencio is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Prevencio

Who are the top strategic acquirers in Prevencio's sector and industry

Top strategic M&A buyers and acquirers in Prevencio's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Prevencio?

Top strategic M&A buyers groups and sectors for Prevencio include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Prevencio's sector and industry vertical

Which are the top PE firms investing in Prevencio's sector and industry vertical?

Top PE firms investing in Prevencio's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Prevencio's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Prevencio's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Prevencio's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Prevencio include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Prevencio's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Prevencio?

The key public trading comparables and valuation benchmarks for Prevencio include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Prevencio for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Prevencio with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Prevencio's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Prevencio with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Prevencio's' sector and industry vertical?

Access recent funding rounds and capital raises in Prevencio's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Prevencio